Skip to content
Subscriber Only

Allergan, TPG Said to Consider Valeant Eye-Surgery Assets

  • Carl Zeiss also said to be interested in surgical assets
  • Valeant may fetch about $2 billion if sale goes ahead
Updated on

Allergan Plc and buyout firm TPG are among potential suitors weighing a bid for Valeant Pharmaceuticals International Inc.’s eye-surgery assets, according to people familiar with the matter.

The surgical products, which are part of Valeant’s Bausch & Lomb unit, have also attracted early interest from Germany’s Carl Zeiss Meditec AG, as well as other private equity firms and possible bidders in Asia, one of the people said, asking not to be identified as the details aren’t public. Valeant could fetch about $2 billion for the assets, the people said.